SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-008208
Filing Date
2024-05-15
Accepted
2024-05-15 07:14:55
Documents
16
Period of Report
2024-05-14
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K adap-20240514x8k.htm   iXBRL 8-K 44969
2 EX-99.1 adap-20240514xex99d1.htm EX-99.1 11762
3 GRAPHIC adap-20240514xex99d1001.jpg GRAPHIC 5334
4 GRAPHIC adap-20240514xex99d1002.jpg GRAPHIC 4097
  Complete submission text file 0001558370-24-008208.txt   198686

Data Files

Seq Description Document Type Size
5 EX-101.SCH adap-20240514.xsd EX-101.SCH 3369
6 EX-101.LAB adap-20240514_lab.xml EX-101.LAB 15972
7 EX-101.PRE adap-20240514_pre.xml EX-101.PRE 10791
19 EXTRACTED XBRL INSTANCE DOCUMENT adap-20240514x8k_htm.xml XML 4916
Mailing Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX
Business Address 60 JUBILEE AVENUE MILTON PARK ABINGDON, OXFORDSHIRE X0 OX14 4RX 44 1235 430000
Adaptimmune Therapeutics PLC (Filer) CIK: 0001621227 (see all company filings)

IRS No.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37368 | Film No.: 24947129
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)